文献速递血栓与止血造血干细胞移植与细胞治疗

腺相关病毒载体整合:对长期疗效与安全性的影响

Adeno-associated viral vector integration: implications for long-term efficacy and safety.
PubMed 文献 · J Thromb Haemost · 2024-08-02

综述总结野生型与重组腺相关病毒(AAV)载体的自然史,重点讨论基因组整合及细胞学影响。AAV 主要通过核内环状双链游离DNA(附加体)持续存在,但野生型与重组AAV均可整合入宿主DNA。部分小鼠研究显示反复整合伴肝细胞癌发生,其他临床前或临床研究未见此现象,整合对长期疗效与安全性的意义尚不明确。

要点

  • AAV载体基因治疗在血友病中已显示长期表达并减少出血。
  • AAV主要经核内环状双链游离DNA持续存在,但也可整合入宿主DNA。
  • 部分小鼠研究见反复整合伴肝细胞癌,其他临床前或临床研究未见。

核心结论

  • 重组AAV载体整合对长期疗效与安全性的意义尚不明确,部分小鼠研究显示反复整合伴肝细胞癌发生,但其他临床前或临床研究未见此现象。

研究设计与样本

  • 综述,总结当前对野生型和重组AAV自然史的认识,重点关注基因组整合及细胞学影响。

主要发现

  • AAV载体基因治疗在血友病中已显示长期表达并减少出血。
  • AAV主要经核内环状双链游离DNA(附加体)持续存在,但野生型与重组AAV研究均显示也可整合入宿主细胞DNA。
  • 野生型AAV感染影响大部分一般人群,被认为无长期后遗症;近期研究在儿童急性肝炎及少数肝细胞癌病例中检测到野生型AAV。
  • 重组AAV治疗后的整合已在临床前和临床研究中报告,部分小鼠研究显示反复整合伴肝细胞癌发生,其他临床前或临床研究未见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adeno-associated virus (AAV) vector gene therapy provides a promising platform for treatment of monogenic inherited disorders. Clinical studies have demonstrated long-term expression with reduction in bleeding using this approach for the treatment of hemophilia. Despite these advances, there are unknowns surrounding the natural history of recombinant AAV (rAAV) vectors and the cellular mechanisms mediating vector persistence. These unknowns underpin questions regarding long-term efficacy and safety. The predominant mechanism via which AAV is proposed to persist is in circular double-stranded extrachromosomal DNA structures (episomes) within the nucleus. Studies of wild-type AAV (WT-AAV) and rAAV have demonstrated that AAV also persists via integration into a host cell's DNA. It is important to determine whether these integration events can mediate expression or could result in any long-term safety concerns. WT-AAV infection affects a large proportion of the general population, which is thought to have no long-term sequelae. Recent studies have highlighted that this WT-AAV has been detected in cases of acute hepatitis in children and in a minority of cases of hepatocellular carcinoma. Integration following treatment using rAAV has also been reported in preclinical and clinical studies. There have been variable reports on the potential implications of integration for rAAV vectors, with data in some murine studies demonstrating recurrent integration with development of hepatocellular carcinoma. These findings have not been seen in other preclinical or clinical studies. In this review, we will summarize current understanding of the natural history of AAV (wild-type and recombinant) with a focus on genomic integration and cellular implications.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Batty P, Lillicrap D. Adeno-associated viral vector integration: implications for long-term efficacy and safety. J Thromb Haemost. 2024. PMID: 39097231. doi:10.1016/j.jtha.2024.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。